1. Home
  2. INAB
  3. INAB News

Latest IN8bio Inc. (INAB) News on February 23, 2025

INAB: Continued Survival in INB-100 Trial
INAB

Zacks Small Cap Research

4 days ago

INAB: Continued Survival in INB-100 Trial

IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML
INAB

GlobeNewswire

9 days ago

IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML

INAB

MT Newswires

12 days ago

IN8bio Says Data Show All Acute Myeloid Leukemia Patients in Early-Stage Study Remain Relapse-Free; Shares Up Pre-Bell

IN8bio Reports Updated Positive Results from Phase 1 Trial of INB-100 in Leukemia Patients
INAB

GlobeNewswire

12 days ago

IN8bio Reports Updated Positive Results from Phase 1 Trial of INB-100 in Leukemia Patients

IN8bio to Present at Biotech Showcase 2025 in San Francisco
INAB

GlobeNewswire

2 months ago

IN8bio to Present at Biotech Showcase 2025 in San Francisco

IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting
INAB

GlobeNewswire

2 months ago

IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting

IN8bio to Present at Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference
INAB

GlobeNewswire

3 months ago

IN8bio to Present at Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference

IN8bio Reports Continued Durable Remissions in Phase 1 Trial of INB-200 in Plenary Oral Presentation at the Society for Neuro-Oncology (SNO) Annual Meeting
INAB

GlobeNewswire

3 months ago

IN8bio Reports Continued Durable Remissions in Phase 1 Trial of INB-200 in Plenary Oral Presentation at the Society for Neuro-Oncology (SNO) Annual Meeting

INAB

Zacks Small Cap Research

3 months ago

INAB: Upcoming Presentations at SNO & ASH

IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
INAB

GlobeNewswire

3 months ago

IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

IN8bio Announces Plenary Oral Presentation at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting
INAB

GlobeNewswire

3 months ago

IN8bio Announces Plenary Oral Presentation at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting

IN8bio Announces Upcoming Presentation at the 2024 American Society of Hematology (ASH) Annual Meeting
INAB

GlobeNewswire

4 months ago

IN8bio Announces Upcoming Presentation at the 2024 American Society of Hematology (ASH) Annual Meeting

INAB

Zacks Small Cap Research

5 months ago

INAB: Restructuring Narrows Focus to AML

IN8bio Announces Pricing of $12.4 Million Private Placement
INAB

GlobeNewswire

5 months ago

IN8bio Announces Pricing of $12.4 Million Private Placement

IN8bio cuts staff and pipeline to focus on AML cell therapy
INAB

Pharmaceutical Technology

6 months ago

IN8bio cuts staff and pipeline to focus on AML cell therapy

IN8bio Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia
INAB

GlobeNewswire

6 months ago

IN8bio Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia

IN8bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference
INAB

GlobeNewswire

6 months ago

IN8bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

INAB: AML & GBM Clinical Update
INAB

Zacks Small Cap Research

6 months ago

INAB: AML & GBM Clinical Update

IN8bio Solidifies Position as a Clinical Leader of Gamma-Delta T Cell Therapy in Oncology with 100% of Treated AML Patients in Complete Remission and Receives FDA Guidance for Registrational Trial of INB-100
INAB

GlobeNewswire

6 months ago

IN8bio Solidifies Position as a Clinical Leader of Gamma-Delta T Cell Therapy in Oncology with 100% of Treated AML Patients in Complete Remission and Receives FDA Guidance for Registrational Trial of INB-100

IN8bio Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
INAB

GlobeNewswire

6 months ago

IN8bio Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

IN8bio to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
INAB

GlobeNewswire

8 months ago

IN8bio to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

INAB: INB-100 Update at EHA24 ¡Olé!
INAB

Zacks Small Cap Research

8 months ago

INAB: INB-100 Update at EHA24 ¡Olé!

IN8bio Decline After Favorable Leukemia Results Could Be Profit-Taking
INAB

Barrons.com

8 months ago

IN8bio Decline After Favorable Leukemia Results Could Be Profit-Taking

INAB

MT Newswires

8 months ago

JonesTrading Adjusts IN8bio's Price Target to $6.50 From $5, Keeps Buy Rating

IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100
INAB

GlobeNewswire

8 months ago

IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100

Edge Total Intelligence Inc. Updates Status of MCTO
INAB

Newsfile

8 months ago

Edge Total Intelligence Inc. Updates Status of MCTO

HEATHERWICK STUDIO UNVEILS ICONIC GLASS CANOPY, THE JEWEL IN THE CROWN OF REIMAGINED OLYMPIA
INAB

CNW Group

8 months ago

HEATHERWICK STUDIO UNVEILS ICONIC GLASS CANOPY, THE JEWEL IN THE CROWN OF REIMAGINED OLYMPIA

Nokia introduces Network Exposure Platform to expand and simplify network API exposure for service providers
INAB

GlobeNewswire

8 months ago

Nokia introduces Network Exposure Platform to expand and simplify network API exposure for service providers

Hyundai Motor Presents Its First Film 'Night Fishing' in Collaboration with K-Movie Star Son Sukku
INAB

CNW Group

8 months ago

Hyundai Motor Presents Its First Film 'Night Fishing' in Collaboration with K-Movie Star Son Sukku

Hofseth Biocare ASA: AGREES CHINA DISTRIBUTION PARTNERSHIP WITH SHANGHAI-BASED LITHY
INAB

GlobeNewswire

8 months ago

Hofseth Biocare ASA: AGREES CHINA DISTRIBUTION PARTNERSHIP WITH SHANGHAI-BASED LITHY

LED Driver with CAN Bus for Dynamic Automotive Interior RGB Lighting
INAB

GlobeNewswire

8 months ago

LED Driver with CAN Bus for Dynamic Automotive Interior RGB Lighting

The sale of Aspo's subsidiary ESL Shipping's Supramax vessels has been completed on June 11 2024
INAB

GlobeNewswire

8 months ago

The sale of Aspo's subsidiary ESL Shipping's Supramax vessels has been completed on June 11 2024

IMAGO AIOS Prime Clinches Red Dot Award for 2024, Expands US Footprint with New Boston Warehouse
INAB

PR Newswire

8 months ago

IMAGO AIOS Prime Clinches Red Dot Award for 2024, Expands US Footprint with New Boston Warehouse

NexTech Solutions Has Agreed to Acquire Rome Research Corporation to Expand Service Offerings and Enhance Mission Support Capabilities
INAB

PR Newswire

8 months ago

NexTech Solutions Has Agreed to Acquire Rome Research Corporation to Expand Service Offerings and Enhance Mission Support Capabilities

INAB

Business Wire

8 months ago

Form 8.3 - Darktrace plc

INAB

Business Wire

8 months ago

Form 8.3 - International Distribution Services plc

US Supreme Court rejects Kroger challenge to Grubhub trademark win
INAB

Reuters

8 months ago

US Supreme Court rejects Kroger challenge to Grubhub trademark win

Dow Jones Falls As AMD Slides On Downgrade; Nvidia Stock Split Takes Effect
INAB

Investor's Business Daily

8 months ago

Dow Jones Falls As AMD Slides On Downgrade; Nvidia Stock Split Takes Effect

GoldATM Supports Growing Consumer Demand for Gold Purchase with New ATMs in North Carolina
INAB

Business Wire

8 months ago

GoldATM Supports Growing Consumer Demand for Gold Purchase with New ATMs in North Carolina

INAB

GlobeNewswire

8 months ago

Middlefield Canadian Income PCC: Net Asset Value(s)

INAB

Business Wire

8 months ago

Form 8.3 - International Paper Company

INAB: INB-200 Update at ASCO24
INAB

Zacks Small Cap Research

9 months ago

INAB: INB-200 Update at ASCO24

IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American Society of Clinical Oncology Annual Meeting
INAB

GlobeNewswire

9 months ago

IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American Society of Clinical Oncology Annual Meeting

IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024
INAB

GlobeNewswire

9 months ago

IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024

INAB

MT Newswires

9 months ago

IN8bio Plans to Report Improvement in Progression-Free Survival of Newly Diagnosed Patients With Glioblastoma Multiforme

IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting
INAB

GlobeNewswire

9 months ago

IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting

INAB: 1Q:24 Results
INAB

Zacks Small Cap Research

9 months ago

INAB: 1Q:24 Results

IN8bio Announces Upcoming Presentation at 2024 European Hematology Association Congress
INAB

GlobeNewswire

9 months ago

IN8bio Announces Upcoming Presentation at 2024 European Hematology Association Congress

IN8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation at ASGCT 2024
INAB

GlobeNewswire

9 months ago

IN8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation at ASGCT 2024

IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
INAB

GlobeNewswire

9 months ago

IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma
INAB

GlobeNewswire

10 months ago

IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma

IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting
INAB

GlobeNewswire

10 months ago

IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

INAB

Zacks Small Cap Research

10 months ago

INAB: Initiating Coverage – Enhancing the Insurgents of the Immune System

IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
INAB

GlobeNewswire

10 months ago

IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference

IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024
INAB

GlobeNewswire

10 months ago

IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024

IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights
INAB

GlobeNewswire

a year ago

IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights

IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024
INAB

GlobeNewswire

a year ago

IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024

IN8bio to Present at Upcoming Investor Conferences
INAB

Business Wire

a year ago

IN8bio to Present at Upcoming Investor Conferences

IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology
INAB

GlobeNewswire

a year ago

IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology

INAB

Reuters

a year ago

US STOCKS SNAPSHOT-Nasdaq opens lower as tech giants disappoint; Fed decision in focus

Magnificent Seven Stocks: Latest News & Market Cap Weighting
INAB

Investor's Business Daily

a year ago

Magnificent Seven Stocks: Latest News & Market Cap Weighting

Arqit awarded ISO 27001 Certification for Information Security Management
INAB

GlobeNewswire

a year ago

Arqit awarded ISO 27001 Certification for Information Security Management

Innovid to Release Fourth Quarter & Full Year 2023 Financial Results on February 27th
INAB

Business Wire

a year ago

Innovid to Release Fourth Quarter & Full Year 2023 Financial Results on February 27th

FNCB Bancorp, Inc. Declares First Quarter 2024 Dividend
INAB

GlobeNewswire

a year ago

FNCB Bancorp, Inc. Declares First Quarter 2024 Dividend

Redwire Selected as Strategic Supplier for Blue Origin’s Trailblazing Blue Ring Space Mobility Platform
INAB

Business Wire

a year ago

Redwire Selected as Strategic Supplier for Blue Origin’s Trailblazing Blue Ring Space Mobility Platform

Cadiz Insiders Placed Bullish Bets Worth US$547.1k
INAB

Simply Wall St.

a year ago

Cadiz Insiders Placed Bullish Bets Worth US$547.1k

INAB

Business Wire

a year ago

PFD, PFO, FFC, FLC and DFP Announce February, March and April Dividends

PDS Biotech to Participate at B. Riley Securities 4th Annual Oncology Conference
INAB

GlobeNewswire

a year ago

PDS Biotech to Participate at B. Riley Securities 4th Annual Oncology Conference

Alpha Modus Announces Intellectual Property License Agreement with GZ6G Technologies Corp.
INAB

GlobeNewswire

a year ago

Alpha Modus Announces Intellectual Property License Agreement with GZ6G Technologies Corp.

Catch the Future in Action: LeddarTech Unveils Its Award-Winning LeddarVision ADAS Products and Technology at CES Las Vegas 2024
INAB

CNW Group

a year ago

Catch the Future in Action: LeddarTech Unveils Its Award-Winning LeddarVision ADAS Products and Technology at CES Las Vegas 2024

INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI™ (toripalimab-tpzi)
INAB

PR Newswire

a year ago

INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI™ (toripalimab-tpzi)

IN8bio Highlights Recent Company Accomplishments and Outlines 2024 Pipeline Goals
INAB

GlobeNewswire

a year ago

IN8bio Highlights Recent Company Accomplishments and Outlines 2024 Pipeline Goals

Village Farms International Announces Launch of Top-Selling Cannabis Brands in the UK
INAB

GlobeNewswire

a year ago

Village Farms International Announces Launch of Top-Selling Cannabis Brands in the UK

LeddarTech Appoints Oren Dayan as Vice-President of Product Line Management and Business Development
INAB

PR Newswire

a year ago

LeddarTech Appoints Oren Dayan as Vice-President of Product Line Management and Business Development

INAB

Business Wire

a year ago

Distribution Dates and Amounts Announced for Eaton Vance Closed-End Funds

Are Investors Undervaluing Galiano Gold (GAU) Right Now?
INAB

Zacks

a year ago

Are Investors Undervaluing Galiano Gold (GAU) Right Now?

Visiox Pharmaceuticals, Inc., a Commercial-Stage Biopharmaceutical Company to be Listed on Nasdaq Through a Business Combination with PowerUp Acquisition Corp.
INAB

GlobeNewswire

a year ago

Visiox Pharmaceuticals, Inc., a Commercial-Stage Biopharmaceutical Company to be Listed on Nasdaq Through a Business Combination with PowerUp Acquisition Corp.

7 Under-the-Radar Stocks Gearing Up for a 2025 Breakthrough
INAB

InvestorPlace

a year ago

7 Under-the-Radar Stocks Gearing Up for a 2025 Breakthrough

INAB

Business Wire

a year ago

Certain Eaton Vance Municipal Closed-End Funds Announce Distribution Updates

4 Low Price-to-Cash Flow Stocks to Navigate the Market in 2024
INAB

Zacks

a year ago

4 Low Price-to-Cash Flow Stocks to Navigate the Market in 2024

BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease
INAB

PR Newswire

a year ago

BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease

The ONE Group Hospitality, Inc. Opens STK Boston
INAB

Business Wire

a year ago

The ONE Group Hospitality, Inc. Opens STK Boston

3 Stocks to Watch From a Prosperous Heavy Construction Industry
INAB

Zacks

a year ago

3 Stocks to Watch From a Prosperous Heavy Construction Industry

Canopy Growth Announces Completed Sale of This Works
INAB

CNW Group

a year ago

Canopy Growth Announces Completed Sale of This Works

The 3 Most Undervalued Penny Stocks to Buy in December
INAB

InvestorPlace

a year ago

The 3 Most Undervalued Penny Stocks to Buy in December

There's A Lot To Like About CSP's (NASDAQ:CSPI) Upcoming US$0.04 Dividend
INAB

Simply Wall St.

a year ago

There's A Lot To Like About CSP's (NASDAQ:CSPI) Upcoming US$0.04 Dividend

CSP Inc. (NASDAQ:CSPI) Q4 2023 Earnings Call Transcript
INAB

Insider Monkey

a year ago

CSP Inc. (NASDAQ:CSPI) Q4 2023 Earnings Call Transcript

With 45% ownership, Spok Holdings, Inc. (NASDAQ:SPOK) has piqued the interest of institutional investors
INAB

Simply Wall St.

a year ago

With 45% ownership, Spok Holdings, Inc. (NASDAQ:SPOK) has piqued the interest of institutional investors

Alpha Modus Appoints Rodney Sperry as Chief Financial Officer
INAB

GlobeNewswire

a year ago

Alpha Modus Appoints Rodney Sperry as Chief Financial Officer

The Zacks Analyst Blog Highlights Biogen, Prothena, AC Immune's and Vaxxinity
INAB

Zacks

a year ago

The Zacks Analyst Blog Highlights Biogen, Prothena, AC Immune's and Vaxxinity

Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Results from Three Clinical Utility Studies
INAB

PR Newswire

a year ago

Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Results from Three Clinical Utility Studies

INAB

Business Wire

a year ago

PFD, PFO, FFC, FLC and DFP Announce December and January Dividends

IN8bio Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in Leukemia
INAB

GlobeNewswire

a year ago

IN8bio Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in Leukemia

IN8bio Announces Pricing of Financing Totaling up to $46.9 Million in Private Placement
INAB

GlobeNewswire

a year ago

IN8bio Announces Pricing of Financing Totaling up to $46.9 Million in Private Placement

Insiders hold 54% of Greenwich LifeSciences, Inc. (NASDAQ:GLSI), and they've been buying recently
INAB

Simply Wall St.

a year ago

Insiders hold 54% of Greenwich LifeSciences, Inc. (NASDAQ:GLSI), and they've been buying recently

Upland FileBound Named a Gold Medalist in the 2023 SoftwareReviews ECM Data Quadrant Report
INAB

Business Wire

a year ago

Upland FileBound Named a Gold Medalist in the 2023 SoftwareReviews ECM Data Quadrant Report

IN8bio Appoints Dr. Corinne Epperly to Board of Directors
INAB

GlobeNewswire

a year ago

IN8bio Appoints Dr. Corinne Epperly to Board of Directors

Seanergy Maritime Releases its 2022 Environmental, Social and Governance Report
INAB

GlobeNewswire

a year ago

Seanergy Maritime Releases its 2022 Environmental, Social and Governance Report

Alto Ingredients, Inc. Extends Term Loan Commitment Period
INAB

GlobeNewswire

a year ago

Alto Ingredients, Inc. Extends Term Loan Commitment Period

IN8bio to Host Investor Call at 8:30 AM ET on Tuesday, December 12 to Discuss Updated Clinical Data from Phase 1 Trial of INB-100 in Patients with Leukemia
INAB

GlobeNewswire

a year ago

IN8bio to Host Investor Call at 8:30 AM ET on Tuesday, December 12 to Discuss Updated Clinical Data from Phase 1 Trial of INB-100 in Patients with Leukemia

Share on Social Networks: